Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

Abstract A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab duri...

Full description

Bibliographic Details
Main Authors: Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-021-00197-w

Internet

https://doi.org/10.1038/s41698-021-00197-w

Similar Items